Q 32 Bio Inc (QTTB)

05:04 AM

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug - MSN

05:04 AM

May 01, 2025

Analysts Provide Insight Into Q32 Bio Inc’s (QTTB) Potential. - Stocksregister

May 01, 2025

May 01, 2025

Closing Figures: Q32 Bio Inc (QTTB)’s Positive Finish at 1.60, Up 2.89 - DWinneX

May 01, 2025

May 01, 2025

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug By Stocktwits - Investing.com India

May 01, 2025

May 01, 2025

Fierce Biotech Layoff Tracker 2025: Pliant cuts 45% of workforce; Arvinas lays off a third of staffers - Fierce Biotech

May 01, 2025

Apr 30, 2025

Q32 Bio Inc (NASDAQ: QTTB) Prices Could Soar To Much Higher Levels In Coming Months - Marketing Sentinel

Apr 30, 2025

Apr 30, 2025

Evaluating QTTB’s financial ratios for a profitable investment - uspostnews.com

Apr 30, 2025

Apr 30, 2025

Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata - marketscreener.com

Apr 30, 2025

Apr 30, 2025

Q32 Bio Inc. Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - marketscreener.com

Apr 30, 2025

Apr 28, 2025

Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace

Apr 28, 2025

Apr 27, 2025

Scotiabank Has Lowered Expectations for goeasy (TSE:GSY) Stock Price - American Banking and Market News

Apr 27, 2025

Apr 27, 2025

Analysts Set Q32 Bio Inc. (NASDAQ:QTTB) PT at $24.71 - Defense World

Apr 27, 2025

Apr 25, 2025

Q32 Bio announces board member resignation By Investing.com - Investing.com Nigeria

Apr 25, 2025

Apr 25, 2025

Q32 Bio IncMark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025 - marketscreener.com

Apr 25, 2025

Apr 25, 2025

Q32 Bio Board Member Mark Iwicki Resigns - TipRanks

Apr 25, 2025

Apr 25, 2025

Q32 Bio announces board member resignation - Investing.com

Apr 25, 2025

Apr 16, 2025

Q32 Bio doses first patient in both parts of SIGNAL-AA trial - TipRanks

Apr 16, 2025

Apr 16, 2025

Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial - marketscreener.com

Apr 16, 2025

Apr 16, 2025

Breakthrough: Q32 Bio's Alopecia Treatment Maintains Effects 7 Months After Last Dose - Stock Titan

Apr 16, 2025

Apr 16, 2025

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - PR Newswire

Apr 16, 2025

Apr 14, 2025

Raymond James Financial Inc. Buys New Stake in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World

Apr 14, 2025

Apr 11, 2025

Q32 Bio Files For Mixed Shelf Of Up To $200 MillionSEC Filing - MarketScreener

Apr 11, 2025

Apr 11, 2025

Wayfair Inc (NYSE: W) Has Dropped -40.68% Year-To-Date (YTD): Any Trouble Coming? - Marketing Sentinel

Apr 11, 2025

Apr 08, 2025

QTTB stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy - MSN

Apr 08, 2025

Apr 08, 2025

QTTB stock touches 52-week low at $1.38 amid market challenges - Investing.com India

Apr 08, 2025

Apr 07, 2025

Arbe Robotics Ltd (NASDAQ: ARBE): How To Buy And When To Buy And Its Performance & Trends - Marketing Sentinel

Apr 07, 2025

Apr 03, 2025

Wayfair Inc (NYSE:W) Up 0.24% Over The Past 30 Days: Any Troubles Ahead? - Marketing Sentinel

Apr 03, 2025

Apr 02, 2025

Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.71 Average Target Price from Brokerages - Defense World

Apr 02, 2025

Apr 01, 2025

Biotech layoff tracker: 21 companies cut 1,000 jobs in Q1 2025 - The Business Journals

Apr 01, 2025

Mar 28, 2025

QTTB stock touches 52-week low at $1.79 amid market challenges By Investing.com - Investing.com South Africa

Mar 28, 2025

Mar 28, 2025

QTTB stock touches 52-week low at $1.79 amid market challenges - Investing.com India

Mar 28, 2025

Mar 24, 2025

Immunosuppressive and Anti-complement Therapies in C3 Glomerulopathy - Medscape

Mar 24, 2025

Mar 24, 2025

Immunosuppressive Therapies in C3 Glomerulopathy - Medscape

Mar 24, 2025

Mar 20, 2025

Oppenheimer maintains Q32 Bio at Outperform, $20 target - Investing.com India

Mar 20, 2025

Mar 20, 2025

Oppenheimer maintains Q32 Bio at Outperform, $20 target By Investing.com - Investing.com UK

Mar 20, 2025

Mar 14, 2025

Wells Fargo & Company Lowers Q32 Bio (NASDAQ:QTTB) Price Target to $15.00 - Defense World

Mar 14, 2025

Mar 12, 2025

Q32 Bio price target lowered to $15 from $16 at Wells Fargo - TipRanks

Mar 12, 2025

Mar 12, 2025

Could Aehr Test Systems (AEHR)’s Current Volatility Hinder Its Future Potential? - Marketing Sentinel

Mar 12, 2025

Mar 12, 2025

Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures - TipRanks

Mar 12, 2025

Mar 12, 2025

Q32 Bio Reports Promising Trial Results and Financials - TipRanks

Mar 12, 2025

Mar 11, 2025

Q32 Bio: Q4 Earnings Snapshot - Midland Daily News

Mar 11, 2025

Mar 11, 2025

Q32 Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 11, 2025

Mar 11, 2025

Q32 Bio Inc. SEC 10-K Report - TradingView

Mar 11, 2025

Mar 11, 2025

Q32 Bio: Q4 Earnings Snapshot -March 11, 2025 at 07:21 am EDT - MarketScreener

Mar 11, 2025